AI drug discovery
The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders and engineers.
Genentech will leverage Medra's Physical AI, Scientific AI and robotics into its lab systems to accelerate drug discovery.
The funds will be used to advance Insilico's drug pipeline and lab, which automates the research and development process, and refine its AI-enabled models and algorithms.
The company, in partnership with Microsoft, aims to develop cancer medicines, followed by treatments for autoimmune diseases and rare conditions.
AMD is making a $20 million equity investment to bolster Absci's drug discovery efforts and expand AMDs accelerators and ROCm software.
The partnership highlights the broader trend of AI-driven innovation in drug discovery and precision medicine.
They will collaborate on identifying novel therapeutic drug candidates for lung cancer.
ProPhet's aim is to bring down the time and cost of finding molecules for new drug targets.
AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules.
The company will use the funds to accelerate its growth, expand the use of its models for different conditions and open an office in Cambridge.